Spyre Therapeutics
SYRE
80.85
+0.74
+0.92%
Spyre Therapeutics
US · SYRE
#1646 by market cap
Listed 1970
80.85
+0.74
+0.92%
Live - 5344 symbols - heartbeat 341s ago
· 2026-10-08 07:00
Pre-market
80.50
-0.43%
After-hours
81.22
+0.46%
Overnight
79.62
-1.52%
- Market cap
- 7.13B
- P/E (TTM)i
- -40.83
- P/Bi
- 7.47
- EPSi
- -1.98
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on SYRE?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 13 analysts
Buy
Avg price target
122.42 +51.4%
Price target rangecurrent 80.85
Low110.00
Avg122.42
High130.00
Buy 92%
Hold 8%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-02 | Wells Fargo | -- | BUY | 115.00 |
| 2026-10-01 | JonesTrading | -- | BUY | 130.00 |
| 2026-10-01 | J.P. Morgan | -- | BUY | 110.00 |
| 2026-09-27 | JonesTrading | -- | BUY | 121.00 |
| 2026-09-10 | Leerink Partners | -- | BUY | 128.00 |
| 2026-09-09 | Wedbush | -- | BUY | 123.00 |
| 2026-09-09 | Jefferies | -- | BUY | 126.00 |
| 2026-09-09 | Leerink Partners | -- | BUY | 128.00 |
| 2026-09-08 | LifeSci Capital | -- | BUY | 116.00 |
| 2026-08-29 | LifeSci Capital | -- | BUY | 116.00 |
| 2026-08-26 | LifeSci Capital | -- | BUY | 116.00 |
| 2026-08-26 | JonesTrading | -- | BUY | 121.00 |
| 2026-08-26 | BTIG | -- | BUY | 121.00 |
| 2026-08-26 | Wedbush | -- | BUY | 123.00 |
| 2026-08-26 | Deutsche Bank | -- | BUY | 127.00 |
| 2026-08-26 | Guggenheim | -- | BUY | 130.00 |
| 2026-08-25 | Wells Fargo | -- | BUY | 115.00 |
| 2026-08-15 | LifeSci Capital | -- | BUY | 129.00 |
| 2026-08-13 | Stifel | -- | BUY | 123.00 |
| 2026-08-12 | JonesTrading | -- | BUY | 140.00 |
| 2026-08-11 | LifeSci Capital | -- | BUY | 129.00 |
| 2026-08-11 | BTIG | -- | BUY | 132.00 |
| 2026-08-11 | Wedbush | -- | BUY | 130.00 |
| 2026-08-08 | LifeSci Capital | -- | BUY | 128.00 |
| 2026-08-06 | Stifel | -- | BUY | 123.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 07:00:13 · For reference only, not investment advice and not tailored to your situation.